Expert questions whether Build Back Better sets new precedent for US drug pricing controls

Could the Build Back Better social spending bill deliver on the promise that previous US administrations have failed to, by passing new federal legislation that would regulate drug prices in the USA?

That is the multi-trillion dollar question asked by Margaret Labban, pricing and market access solutions manager at UK-based consultants Global Pricing Innovations.

The bill recently passed in the House of Representatives and includes unprecedented drug pricing controls for certain drugs covered under Medicare. It establishes inflation rebates that could notably temper the rate of drug price increases over time. The Senate is anticipated to pass a version of the bill soon.